| HealthCare Royalty–ADC Therapeutics: antibody-drug conjugates, 202108 acquisition $225m upfront + $100m milestones royalty rights to Zynlonta + Cami |
2021-08-26 |
| Cardior Pharmaceuticals–ABP (NL): investment, 202108 financing round Series B totalling €64m incl new + lead investor Inkef Capital |
2021-08-25 |
| Cardior Pharmaceuticals–BioMedPartners: investment, 202108 financing round Series B totalling €64m incl existing + co-investor BioMedPartners |
2021-08-25 |
| Cardior Pharmaceuticals–BMS: investment, 202108 financing round Series B totalling €64m incl existing + co-investor BMS |
2021-08-25 |
| Cardior Pharmaceuticals–Fund+: investment, 202108 financing round Series B totalling €64m incl new + co-investor Fund+ |
2021-08-25 |
| Cardior Pharmaceuticals–Germany (govt): investment, 202108 financing round Series B totalling €64m incl new + co-investor Coparion |
2021-08-25 |
| Cardior Pharmaceuticals–Hadean Ventures: investment, 202108 financing round Series B totalling €64m incl new + co-investor Hadean Ventures |
2021-08-25 |
| Cardior Pharmaceuticals–High-Tech Gründerfonds: investment, 202108 financing round Series B totalling €64m incl existing + co-investor HTGF |
2021-08-25 |
| Cardior Pharmaceuticals–Life Sciences Partners: investment, 202108 financing round Series B totalling €64m incl existing + co-investor LSP |
2021-08-25 |
| Cardior Pharmaceuticals–SEVERAL: investment, 202108 financing round Series B €64m led by new investor Inkef Capital |
2021-08-25 |
| Cardior Pharmaceuticals–Sunstone Life Science: investment, 202108 financing round Series B totalling €64m incl new + co-investor Sunstone |
2021-08-25 |
| Cardior Pharmaceuticals–Trophic Communications: public relations, 202108 service existent by Trophic Communications |
2021-08-25 |
| FarmInsect–5x Ventures: investment, 202108 2nd seed financing round totalling 7-digit € incl co-investor 5x Ventures |
2021-08-17 |
| FarmInsect–Bavaria (govt): investment, 202108 2nd seed financing round totalling 7-digit € incl co-lead investor Bayern Kapital |
2021-08-17 |
| FarmInsect–Genea Invest: investment, 202108 2nd seed financing round totalling 7-digit € incl co-investor Genea Invest |
2021-08-17 |
| FarmInsect–High-Tech Gründerfonds: investment, 202108 2nd seed financing round totalling 7-digit € incl co-lead investor HTGF |
2021-08-17 |
| FarmInsect–Industrial Innovators Initiative: investment, 202108 2nd seed financing round totalling 7-digit € incl co-investor III |
2021-08-17 |
| FarmInsect–OTHER: investment, 202108 2nd seed financing round totalling 7-digit € incl business angels as co-investors |
2021-08-17 |
| FarmInsect–SEVERAL: investment, 202108 2nd seed financing round 7-digit € co-led by HTGF + Bayern Kapital |
2021-08-17 |
| Bayer–Berkeley Lights: plant research, 202108 collab multi-year €na RnD seeds and traits using Berkeley Lights Platform |
2021-08-11 |
| Visus Therapeutics–Life Sciences Partners: investment, 202108 financing round totalling $20m in preferred stock incl new + lead investor LSP |
2021-08-10 |
| Visus Therapeutics–SEVERAL: investment, 202108 financing round $20m in preferred stock led by new investor LSP |
2021-08-10 |
| OncXerna Therapeutics–Qiagen: molecular companion diagnostics, 202108– collab developm Xerna TME panel as NGS CDx for navicixizumab |
2021-08-09 |
| Qiagen–OncXerna Therapeutics: molecular companion diagnostics, 202108– license non-excl to Xerna TME panel as NGS CDx for Qiagen |
2021-08-09 |
| SolasCure–Seneca Partners: investment, 201808–202108 financing round Series A totalling £15m incl co-investor Seneca Partners |
2021-08-09 |
| Vividion Therapeutics–Bayer: investment, 202108– acquisition $1.5b upfront + $500k milestones ANNOUNCED |
2021-08-05 |
| Evotec–SEVERAL: investment, 202108– proposed offering of ADSs via secondary US listing at Nasdaq Global Select Market FILED |
2021-08-02 |
| T-Knife–SEVERAL: investment, 202108 financing round Series B $110m led by new investor Fidelity Management and Research |
2021-08-02 |
| Topas Therapeutics–BioMedPartners: investment, 202107 financing round Series B extension €18m incl existing investor BioMedPartners |
2021-07-29 |
| Topas Therapeutics–Boehringer: investment, 202107 financing round Series B extension €18m incl existing investor BIVF |
2021-07-29 |
| Topas Therapeutics–EMBL: investment, 202107 financing round Series B extension €18m incl existing investor EMBL Ventures |
2021-07-29 |
| Topas Therapeutics–Epidarex Capital: investment, 202107 financing round Series B extension €18m incl existing investor Epidarex Capital |
2021-07-29 |
| Topas Therapeutics–Evotec: investment, 202107 financing round Series B extension €18m incl existing investor Evotec |
2021-07-29 |
| Topas Therapeutics–Gimv: investment, 202107 financing round Series B extension €18m incl existing investor Gimv |
2021-07-29 |
| Topas Therapeutics–SEVERAL: investment, 202107 financing round Series B extension €18m bringing total round to €40m incl all existing investors |
2021-07-29 |
| Topas Therapeutics–Vesalius Biocapital: investment, 202107 financing round Series B extension €18m incl existing investor Vesalius Biocapital III |
2021-07-29 |
| Xell AG–Sartorius: investment, 202107 acquisition €50m plus two revenue-based earn-out components in 2022 to 2025 |
2021-07-29 |
| Evitria–Atlas Antibodies: investment, 202107– acquisition of Evitria by Atlas Antibodies AB |
2021-07-28 |
| HMNC–SEVERAL: credit, 202107 convertible debt financing €9m from renowned family offices incl Maschmeyer + Jahr + Gutmann |
2021-07-28 |
| Artios Pharma–SEVERAL: investment, 202107 financing round Series C £110m ($153m) co-led by Omega Funds + TCG X |
2021-07-27 |
| Cevec–North Rhine-Westphalia (govt): investment, 202107 growth financing round incl investor NRW.Bank |
2021-07-27 |
| Cevec–SEVERAL: investment, 202107 growth financing round with investor NRW.Bank et al |
2021-07-27 |
| Axa–SEVERAL: investment, 202107 raising of €1.9b equity by AXA IM Alts to invest in European Life Sciences primarly via Kadans Science Partner |
2021-07-26 |
| Relief Therapeutics–SEVERAL: investment, 202107 private placement CHF15m with 71.4m common stock at CHF0.21/share to two US institutional investors |
2021-07-26 |
| Sophia Genetics–SEVERAL: investment, 202107 US IPO $234m+$35.1m with 13m+1.95m ordinary shares at $18/Share at Nasdaq Global Select Market |
2021-07-22 |
| 3a-Diagnostics–XPhyto Therapeutics: investment, 202107– 202110 acqisition 100% €400k upfront + €3.5m at closing ANNOUNCED |
2021-07-20 |
| NanoSyrinx–Merck (DE): investment, 202107 seed financing round totalling £6.2m incl existing + co-lead investor M Ventures |
2021-07-19 |
| NanoSyrinx–SEVERAL: investment, 202107 seed financing round £6.2m co-led by Octopus Ventures + M Ventures |
2021-07-19 |
| Dopavision–Akampion: public relations, 202107 service existent by Akampion |
2021-07-14 |
| Dopavision–Boehringer: investment, 202107 financing round Series A totalling €12m incl existing + co-investor BIVF |
2021-07-14 |
| Dopavision–BPCE: investment, 202107 financing round Series A totalling €12m incl new + lead investor Seventure Partners |
2021-07-14 |
| Dopavision–Eternity.Health: investment, 202107 financing round Series A totalling €12m incl existing + co-investor Ababax Health |
2021-07-14 |
| Dopavision–Novartis: investment, 202107 financing round Series A totalling €12m incl new + co-investor Novartis Pharmaceuticals |
2021-07-14 |
| Dopavision–SEVERAL: investment, 202107 financing round Series A €12m led by new investor Seventure Partners |
2021-07-14 |
| Immunic–SEVERAL: investment, 202107 underwritten public offering $45m with 4.5m shares common stock at $10/share |
2021-07-14 |
| InfanDx–SEVERAL: investment, 202107 financing round Series A first closing €4m from new investor Alluti GmbH + existing investors |
2021-07-13 |
| Vectura–Philip Morris: investment, 202107– acquisition recommended cash tender offer GBP852m at150p/share |
2021-07-09 |
| Theolytics–Merck (DE): investment, 202107 financing round Series A expansion incl new investor M Ventures |
2021-07-08 |
| Theolytics–Otsuka: investment, 202107 financing round Series A expansion incl existing investor Taiho Ventures |
2021-07-08 |
| Theolytics–SEVERAL: investment, 202107 financing round Series A expansion incl new investor M Ventures |
2021-07-08 |
| Theolytics–Univ Oxford: investment, 202107 financing round Series A expansion incl existing investor Univ Oxford |
2021-07-08 |
| Cutanos–High-Tech Gründerfonds: investment, 202107 1st financing round incl investor HTGF |
2021-07-05 |
| Cutanos–IST Cube: investment, 202107 1st financing round incl investor IST Cube |
2021-07-05 |
| Cutanos–Khanu Management: investment, 202107 1st financing round incl investor KHAN Technology Transfer Fund I |
2021-07-05 |
| Cutanos–OTHER: investment, 202107 1st financing round incl a private investor |
2021-07-05 |
| Cutanos–SEVERAL: investment, 202107 1st financing round with KHAN-I + HTGF + IST Cube + another private investor |
2021-07-05 |
| CellGenix–Sartorius: investment, 202107 acquisition 51% share for €100m cash by SSB with planned acquisition of remaining shares until 2026 |
2021-07-02 |
| Fertin Pharma–Philip Morris: investment, 202107– acquisition DKK5.1b ($820m) from EQT + Bagger-Sørensen ANNOUNCED |
2021-07-01 |
| Nestlé–Seres Therapeutics: microbiome-based drug, 202107– license North America $175m upfront + $350m milestones + 50% of commercial profits |
2021-07-01 |
| Zukunftsfonds Heilbronn–Ampersand: investment, 202107 acquisition of majority share in PPS from ZFHN and merger with portfolio company GeneWerk |
2021-07-01 |
| Promethera–SEVERAL: investment, 202106– financing round €20m incl €10m from Shang Ying Intl Holdings Ltd (HK) |
2021-06-30 |
| Boehringer–WPP: public releations, 202106c supply service Boehringer is among largest + long-term health clients of Ogilvy Health |
2021-06-28 |
| Polyphor–LifeSci: public relations, 202106 supply service existent LifeSci Advisors is media + IR contact for Polyphor |
2021-06-28 |
| Merck (DE)–Nucleai MD: AI-based biomarker discovery, 202106– long-term collab using ATOM platform for cancer biomarker discovery |
2021-06-24 |
| RheinCell Therapeutics–Catalent: investment, 202106– acquisition of RheinCell by Catalent ANNOUNCED |
2021-06-24 |
| FundaMental Pharma–High-Tech Gründerfonds: investment, 202106 seed funding from HTGF |
2021-06-23 |
| Leukocare–Petrichor Healthcare: credit, 202106– convertible loan totalling $15m incl Petrichor HCM |
2021-06-23 |
| Leukocare–Petrichor Healthcare: investment, 202106 equity investment $2.5m from Petrichor HCM |
2021-06-23 |
| Leukocare–SEVERAL: credit, 202106– convertible loan $15m led by Petrichor HCM + incl existing shareholders |
2021-06-23 |
| Monte Rosa Therapeutics–SEVERAL: investment, 202106 IPO $222.3m+$33.345m with 11.7m+1.755m shares common stock at Nasdaq Global Select Market |
2021-06-23 |
| Paramit–Tecan: investment, 202106– acquisition $1b from Altaris Capital Partners LLC ANNOUNCED |
2021-06-23 |
| 908 Devices–Sartorius: bioprocess control technology, 202106 collab product integration Rebel media analyzer with SIMCA data exploratory tool |
2021-06-22 |
| 908 Devices–Securecell: bioprocess control technology, 202106 collab product integration Rebel media analyzer with Lucullus PIMS |
2021-06-22 |
| Sirion Biotech–PerkinElmer: investment, 202106– acquisition by PerkinElmer ANNOUNCED |
2021-06-22 |
| Chemic Laboratories–Solvias: investment, 202106 acquisition €na by Solvias |
2021-06-17 |
| Ochre Bio–Apollo Ventures: investment, 202106 seed financing round totalling $9.6m incl co-investor Apollo Health Ventures |
2021-06-16 |
| Ochre Bio–Backed VC: investment, 202106 seed financing round totalling $9.6m incl co-investor Backed VC |
2021-06-16 |
| Ochre Bio–Hermes-Epitek: investment, 202106 seed financing round totalling $9.6m incl co-investor Hermes-Epitek |
2021-06-16 |
| Ochre Bio–Hoxton: investment, 202106 seed financing round totalling $9.6m incl co-investor Hoxton |
2021-06-16 |
| Ochre Bio–Khosla Ventures: investment, 202106 seed financing round totalling $9.6m incl lead investor Khosla Ventures |
2021-06-16 |
| Ochre Bio–Selvedge: investment, 202106 seed financing round totalling $9.6m incl co-investor Selvedge |
2021-06-16 |
| Ochre Bio–SEVERAL: investment, 202106 seed financing round $9.6m led by Khosla Ventures |
2021-06-16 |
| Alentis Therapeutics–Bellevue: investment, 202106 financing round Series B totalling CHF60m incl existing + co-investor BB Pureos Bioventures |
2021-06-15 |
| Alentis Therapeutics–BioMedPartners: investment, 202106 financing round Series B totalling CHF60m incl existing + co-investor BioMed Partners |
2021-06-15 |
| Alentis Therapeutics–France (govt): investment, 202106 financing round Series B totalling CHF60m incl existing + co-investor Bpifrance InnoBio 2 Fund |
2021-06-15 |
| Alentis Therapeutics–High-Tech Gründerfonds: investment, 202106 financing round Series B totalling CHF60m incl existing + co-investor HTGF |
2021-06-15 |
| Alentis Therapeutics–Jeito Capital: investment, 202106 financing round Series B totalling CHF60m incl new + co-investor Jeito Capital |
2021-06-15 |
| Alentis Therapeutics–Morningside: investment, 202106 financing round Series B totalling CHF60m incl new + lead investor Morningside Ventures |
2021-06-15 |
| Alentis Therapeutics–Schroders: investment, 202106 financing round Series B totalling CHF60m incl existing + co-investor Schroders Capital |
2021-06-15 |
| Alentis Therapeutics–SEVERAL: investment, 202106 financing round Series B CHF60m led by Morningside Venture Investments |
2021-06-15 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
